BioArctic Mesenkia glioblastoma research collaboration
Analysis based on 6 articles · First reported Aug 19, 2026 · Last updated Aug 19, 2026
The collaboration is a positive development for BioArctic, potentially expanding its pipeline into oncology and validating its BrainTransporter platform, which could support its stock price. For Mesenkia, the partnership provides validation and resources to advance its glioblastoma program, though both companies remain in early preclinical stages with no immediate revenue impact.
On August 19, 2026, BioArctic and Bicara Therapeutics announced a research collaboration agreement to develop a novel antibody-based treatment for glioblastoma, an aggressive brain cancer. The collaboration combines BioArctic's BrainTransporter technology with Mesenkia's KITAIbodies platform, targeting the HVEM protein on tumor cells. BioArctic will generate a drug candidate and both companies will conduct preclinical studies. This marks BioArctic's entry into oncology and expands its BrainTransporter pipeline beyond neurodegenerative diseases. Mesenkia, a preclinical company founded on science from Uppsala University and the University of Tokyo, aims to address the high unmet medical need in glioblastoma. The agreement was disclosed on August 19, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard